Résumé
L’IRM est une technique d’imagerie peu sensible en termes de concentration détectable, mais offre des potentialités intéressantes pour la caractérisation des tumeurs et l’appréciation des traitements, car le signal peut être sensibilisé à de multiples paramètres (diffusion et perfusion, perméabilité vasculaire, oxygénation sanguine). L’étude de la microcirculation et l’étude de la fonction macrophagique bénéficient de l’emploi des agents de contraste. La spectroscopie RMN permet dans certaines tumeurs une caractérisation biochimique du tissu ou de sa réponse au traitement.
Abstract
MRI demonstrates low sensitivity in detecting concentrations of metabolites, but can be set to detect a large number of other parameters, including perfusion, diffusion, and oxygenation patterns. Contrast agents allow the investigation of microvasculature and the visualisation of phagocytosis. For some tumours, MR spectroscopy makes it possible to determine the biochemical profile of tissues and their responses to various treatments.
This is a preview of subscription content, log in via an institution to check access.
Références
Brauer M (2003) In vivo monitoring of apoptosis. Prog Neuropsychopharmacol Biol Psychiatr 27: 323–31
Choyke PL, Dwyer AJ, Knopp MV (2003) Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 17: 509–20
De Bazelaire C, Rofsky NM, Duhamel G, et al. (2005) Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma. Acad Radiol 12(3):347–57
Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10: 254–9
Kastler B, Vetter D, Patay Z, et al. (2006) Comprendre l’IRM: manuel d’autoapprentissage, Masson, Paris
Kwock L, Smith JK, Castillo M, et al. (2006) Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 7: 859–68
Padhani AR, Husband JE (2001) Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol 56: 607–20
Reinsberg SA, Payne GS, Riches SF, et al. (2007) Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection. Am J Roentgenol 188: 91–8
Taylor JS, Tofts PS, Port R, et al. (1999) MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10: 903–7
Tofts PS, Brix G, Buckley DL, et al. (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223–32
Yankeelov TE, Luci JJ, Lepage M, et al. (2005) Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 23: 519–29
Young RJ, Knopp EA (2006) Brain MRI: tumor evaluation. J Magn Reson Imaging 24: 709–24
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Leroy-Willig, A. Les outils de l’IRM fonctionnelle pour l’oncologie. Oncologie 9, 268–274 (2007). https://doi.org/10.1007/s10269-007-0635-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-007-0635-z